Visual field and ocular safety during short-term vigabatrin treatment in cocaine abusers

American Journal of Ophthalmology

Volumn 154, Issue 2, 2012, Pages

  Berezina, Tamara L ^a   Khouri, Albert S ^a   Winship, M Douglas ^b   Fechtner, Robert D ^a  

^a INSTITUTE OF OPHTHALMOLOGY AND VISUAL SCIENCE   (United States)

^b Catalyst Pharmaceutical Partners Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; VIGABATRIN;

ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; VISUAL ACUITY; VISUAL FIELD;

EID: 84866402681     PISSN: 00029394     EISSN: 18791891     Source Type: Journal    
DOI: 10.1016/j.ajo.2012.02.026     Document Type: Article

References (40)

1. Gram L, Lyon BB, Dam M. Gamma-vinyl-GABA: a singleblind trial in patients with epilepsy. Acta Neurol Scand 1983;68(1):34 -39.
2. Schechter PJ, Hanke NF, Grove J, Huebert N, Sjoerdsma A. Biochemical and clinical effects of gamma-vinyl GABA in patients with epilepsy. Neurology 1984;34(2):182-186.
3. Chiron C, Dulac O, Luna D, et al. Vigabatrin in infantile spasms. Lancet 1990;335(8685):363-364.
4. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997;314 (7075):180 -181.
5. Kälviäinen R, Nousiainen I, Mäntyjärvi M, et al. Vigabatrin, a gabaergic antiepileptic drug, causes concentric visual field defects. Neurology 1999;53(5):922-926.
6. Hardus P, Verduin WM, Postma G, et al. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000;41(5):581-587.
7. Newman WD, Tocher K, Acheson JF. Vigabatrin associated visual field loss: a clinical audit to study prevalence, drug history and effects of drug withdrawal. Eye (Lond) 2002; 16(5):567-571.
8. Gonzalez P, Sills GJ, Parks S, et al. Binasal visual field defects are not specific to vigabatrin. Epilepsy Behav 2009;16(3): 521-526.
9. Wild JM, Chiron C, Ahn H, et al. Visual field loss in patients with refractory partial epilepsy treated with vigabatrin: final results from an open-label, observational, multicentre study. CNS Drugs 2009;23(11):965-982.
10. Graniewsky-Wijnands HS, van der Torren K. Electro-ophthalmological recovery after withdrawal from vigabatrin. Doc Ophthalmol 2002;104(2):189 -194.
11. Schmidt T, Rüther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B. Is visual field constriction in epilepsy patients treated with vigabatrin reversible? J Neurol 2002;249(8):1066-1071.
12. Hardus P, Verduin W, Berendschot T, Postma G, Stilma J, van Veelen C. Vigabatrin: long term follow-up of electrophysiology and visual field examinations. Acta Ophthalmol Scand 2003;81(5):459-465.
13. Brodie JD, Figueroa E, Laska EM, Dewey SL. Safety and efficacy of gamma-vinyl GABA (GVG) for the treatment of methamphetamine and/or cocaine addiction. Synapse 2005; 55(2):122-125.
14. Fechtner RD, Khouri AS, Figueroa E, et al. Short-term treatment of cocaine and/or methamphetamine abuse with vigabatrin: ocular safety pilot results. Arch Ophthalmol 2006;124(9):1257-1262.
15. Ferris FL 3rd, Bailey I. Standardizing the measurement of visual acuity for clinical research studies: Guidelines from the Eye Care Technology Forum. Ophthalmology 1996;103:181-182.
16. Berezina TL, Khouri AS, Kolomeyer AM, Clancy PS, Fechtner RD. Peripheral visual field thresholds using Humphrey Field Analyzer program 60-4 in normal eyes. Eur J Ophthalmol 2011;21(4):415-421.
17. Schmitz B, Schmidt T, Jokiel B, Pfeiffer S, Tiel-Wilck K, Rüther K. Visual field constriction in epilepsy patients treated with vigabatrin and other antiepileptic drugs: a prospective study. J Neurol 2002;249(4):469-475.
18. Besch D, Kurtenbach A, Apfelstedt-Sylla E, et al. Visual field constriction and electrophysiological changes associated with vigabatrin. Doc Ophthalmol 2002;104(2):151-170.
19. Riise P, Fledelius HC, Rogvi-Hansen B. Vigabatrin and visual field defects. A Danish material with evaluation of different screening methods. Ugeskr Laager 2003;165(10):1034-1038.
20. Fledelius HC. Vigabatrin-associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 2003;81(1):41-46.
21. Gaily E, Jonsson H, Lappi M. Visual fields at school-age in children treated with vigabatrin in infancy. Epilepsia 2009; 50(2):206 -216.
22. Jensen H, Sjö O, Uldall P, Gram L. Vigabatrin and retinal changes. Doc Ophthalmol 2002;104(2):171-180.
23. Kinirons P, Cavalleri GL, O'Rourke D, et al. Vigabatrin retinopathy in an Irish cohort: lack of correlation with dose. Epilepsia 2006;47(2):311-317.
24. Clayton LM, Dévilé M, Punte T, et al. Retinal nerve fiber layer thickness in Vigabatrin-exposed patients. Ann Neurol 2011;69(5):845-854.
25. You SJ, Ahn H, Ko TS. Vigabatrin and visual field defects in pediatric epilepsy patients. J Korean Med Sci 2006;21(4): 728-732.
26. Agrawal S, Mayer DL, Hansen RM, Fulton AB. Visual fields in young children treated with vigabatrin. Optom Vis Sci 2009;86(6):767-773.
27. Wild JM, Martinez C, Reinshagen G, Harding GFA. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999;40(12):1784 -1794.
28. Best JL, Acheson JF. The natural history of Vigabatrin associated visual field defects in patients electing to continue their medication. Eye (Lond) 2005;19(1):41-44.
29. Tseng YL, Lan MY, Lai SL, Huang FC, Tsai JJ. Vigabatrinattributable visual field defects in patients with intractable partial epilepsy. Acta Neurol Taiwan 2006;15(4):244 -250.
30. Conway M, Cubbidge RP, Hosking SL. Visual field severity indices demonstrate dose-dependent visual loss from vigabatrin therapy. Epilepsia 2008;49(1):108 -116.
31. Kjellström U, Kjellström S, Bruun A, Andréasson S, Ponjavic V. Retinal function in rabbits does not improve 4-5 months after terminating treatment with vigabatrin. Doc Ophthalmol 2006;112(1):35-41.
32. Ingster-Moati I, Orssaud C. Ophthalmological monitoring protocol for patients treated with long-term antimalarials or vigabatrin. J Fr Ophtalmol 2009;32(1):83-88.
33. Sergott RC, Wheless JW, Smith MC, et al. Evidence-based review of recommendations for visual function testing in patients treated with vigabatrin. Neuro-Ophthalmology 2010; 34(1):20-35.
34. Hawker MJ, Astbury NJ. The ocular side effects of vigabatrin (Sabril): information and guidance for screening. Eye 2008; 22(9):1097-1098.
35. Sills GJ, Butler E, Forrest G, Ratnaraj N, Patsalos PN, Brodie MJ. Vigabatrin, but not gabapentin or topiramate, produces concentration-related effects on enzymes and intermediates of the GABA shunt in rat brain and retina. Epilepsia 2003;44(7):886-892.
36. Moseng L, Saeter M, Mørch-Johnsen GH, et al. Retinal nerve fibre layer attenuation: clinical indicator for vigabatrin toxicity. Acta Ophthalmol 2011;89(5):452-458.
37. Lawthom C, Smith PE, Wild JM. Nasal retinal nerve fiber layer attenuation: a biomarker for vigabatrin toxicity. Ophthalmology 2009;116(3):565-571.
38. Ardagil Akçakaya A, Gökçeer S, Erbil HH, et al. Detecting retinal vigabatrin toxicity in patients with partial symptomatic or cryptogenic epilepsy. Eur J Ophthalmol 2010;20(4):763-769.
39. Jammoul F, Wang Q, Nabbout R, et al. Taurine deficiency is a cause of vigabatrin-induced retinal phototoxicity. Ann Neurol 2009;65(1):98 -107.
40. Jammoul F, Dégardin J, Pain D, et al. Taurine deficiency damages photoreceptors and retinal ganglion cells in vigabatrin- treated neonatal rats. Mol Cell Neurosci 2010;43(4): 414-421.